Michael C Frühwald1, Stefan Rutkowski. 1. I. Klinik für Kinder und Jugendliche, Klinikum Augsburg. Michael.Fruehwald@Klinikum-Augsburg.de
Abstract
BACKGROUND: Multimodal treatment approaches for children with tumors of the central nervous system (CNS) have markedly contributed to improved survival. Before 1970, the survival rate among children with medulloblastoma, the most common malignant CNS tumor in children, was about 20%. At present, in contrast, cure can be achieved in more than 75% of children with a favorable constellation of risk factors. In this review article for clinicians, we give an overview of the current understanding of the pathology, presenting manifestations, early diagnosis, and treatment of CNS tumors in children and adolescents. METHODS: We report the research findings of the German Treatment Network "HIT" and selectively review the pertinent literature. RESULTS: Treatment-optimizing clinical trials have improved survival from all types of CNS tumors in children and adolescents. Biological features of the tumors now serve as the basis for improved stratification for multimodal, risk-adapted treatment. Targeted biological strategies are being developed. Difficulties remain, however, in the care of infants with CNS tumors and in the treatment of metastatic disease, tumors of certain histological types, and tumors in certain anatomical sites. Many of the affected children suffer from late effects of their disease and its treatment that can irreversibly impair their development. CONCLUSION: Children with a suspected or confirmed diagnosis of brain tumor should be referred early to a center with the relevant experience. Standardized diagnostic and therapeutic methods have markedly improved the chance of cure. Current research on molecular signaling pathways seems likely to lead to the development of new treatments, particularly for tumors currently associated with lower rates of survival. The long-term side effects of treatment must be systematically monitored so that they can be avoided in future, and so that appropriate support measures can be provided to the affected children.
BACKGROUND: Multimodal treatment approaches for children with tumors of the central nervous system (CNS) have markedly contributed to improved survival. Before 1970, the survival rate among children with medulloblastoma, the most common malignant CNS tumor in children, was about 20%. At present, in contrast, cure can be achieved in more than 75% of children with a favorable constellation of risk factors. In this review article for clinicians, we give an overview of the current understanding of the pathology, presenting manifestations, early diagnosis, and treatment of CNS tumors in children and adolescents. METHODS: We report the research findings of the German Treatment Network "HIT" and selectively review the pertinent literature. RESULTS: Treatment-optimizing clinical trials have improved survival from all types of CNS tumors in children and adolescents. Biological features of the tumors now serve as the basis for improved stratification for multimodal, risk-adapted treatment. Targeted biological strategies are being developed. Difficulties remain, however, in the care of infants with CNS tumors and in the treatment of metastatic disease, tumors of certain histological types, and tumors in certain anatomical sites. Many of the affected children suffer from late effects of their disease and its treatment that can irreversibly impair their development. CONCLUSION:Children with a suspected or confirmed diagnosis of brain tumor should be referred early to a center with the relevant experience. Standardized diagnostic and therapeutic methods have markedly improved the chance of cure. Current research on molecular signaling pathways seems likely to lead to the development of new treatments, particularly for tumors currently associated with lower rates of survival. The long-term side effects of treatment must be systematically monitored so that they can be avoided in future, and so that appropriate support measures can be provided to the affected children.
Authors: Stefan Rutkowski; Bruce Cohen; Jonathan Finlay; Roberto Luksch; Vita Ridola; Dominique Valteau-Couanet; Junichi Hara; Maria-Luisa Garre; Jacques Grill Journal: Pediatr Blood Cancer Date: 2010-04 Impact factor: 3.167
Authors: G Calaminus; M Bamberg; D Harms; H Jürgens; R D Kortmann; N Sörensen; O D Wiestler; U Göbel Journal: Neuropediatrics Date: 2005-04 Impact factor: 1.947
Authors: Johannes E A Wolff; Pablo Hernaiz Driever; Bernhard Erdlenbruch; Rolf D Kortmann; Stefan Rutkowski; Torsten Pietsch; Crystal Parker; Monica Warmuth Metz; Astrid Gnekow; Christof M Kramm Journal: Cancer Date: 2010-02-01 Impact factor: 6.860
Authors: Steven De Vleeschouwer; Steffen Fieuws; Stefan Rutkowski; Frank Van Calenbergh; Johannes Van Loon; Jan Goffin; Raf Sciot; Guido Wilms; Philippe Demaerel; Monika Warmuth-Metz; Niels Soerensen; Johannes E A Wolff; Sabine Wagner; Eckhart Kaempgen; Stefaan W Van Gool Journal: Clin Cancer Res Date: 2008-05-15 Impact factor: 12.531
Authors: Susan N Chi; Mary Ann Zimmerman; Xiaopan Yao; Kenneth J Cohen; Peter Burger; Jaclyn A Biegel; Lucy B Rorke-Adams; Michael J Fisher; Anna Janss; Claire Mazewski; Stewart Goldman; Peter E Manley; Daniel C Bowers; Anne Bendel; Joshua Rubin; Christopher D Turner; Karen J Marcus; Liliana Goumnerova; Nicole J Ullrich; Mark W Kieran Journal: J Clin Oncol Date: 2008-12-08 Impact factor: 44.544
Authors: Marcel Kool; Jan Koster; Jens Bunt; Nancy E Hasselt; Arjan Lakeman; Peter van Sluis; Dirk Troost; Netteke Schouten-van Meeteren; Huib N Caron; Jacqueline Cloos; Alan Mrsić; Bauke Ylstra; Wieslawa Grajkowska; Wolfgang Hartmann; Torsten Pietsch; David Ellison; Steven C Clifford; Rogier Versteeg Journal: PLoS One Date: 2008-08-28 Impact factor: 3.240
Authors: Ruby Del Risco Kollerud; Lisa A Cannon-Albright; Hege S Haugnes; Ellen Ruud; Magne Thoresen; Per Nafstad; Karl Gerhard Blaasaas; Øyvind Naess; Bjørgulf Claussen Journal: Pediatr Blood Cancer Date: 2020-05-21 Impact factor: 3.167
Authors: Rebekka Unland; Kornelius Kerl; Sabrina Schlosser; Nicole Farwick; Tanja Plagemann; Birigit Lechtape; Steven C Clifford; Jonas H Kreth; Joachim Gerss; Jörg Mühlisch; Günther H S Richter; Martin Hasselblatt; Michael C Frühwald Journal: J Neurooncol Date: 2013-11-22 Impact factor: 4.130